Prothena Corp Public Ltd Co has disclosed important share transactions involving William P. Scully, a ten-percent owner of the company. The recent filings indicate that Scully acquired and disposed of a substantial number of shares, which could reflect his confidence in Prothena's future prospects.

On November 6, 2026, Scully disposed of 916,444 ordinary shares, leaving him with 837,000 shares following the transaction. Just a few days later, on November 9, he acquired 140,000 shares at an average price of approximately $8.53 per share, increasing his total holdings to 977,000 shares. These transactions are significant as they highlight the ongoing activity and interest from key stakeholders in Prothena.

Background

Prothena Corp Public Ltd Co, traded under the ticker PRTA on the Nasdaq, operates within the pharmaceutical preparations sector (SIC 2834). The company is based in Dublin, Ireland, and focuses on developing therapies for diseases associated with protein misfolding and neurodegeneration. It has been active in the market, with its latest filings indicating a robust engagement with investors.

What the Filing Says

The recent filing, accession number 0001045463-26-000024, details two significant transactions by Scully. The first transaction involved the disposal of 916,444 shares on November 6, 2026. The second transaction, which occurred on November 9, involved the acquisition of 140,000 shares at a weighted average price of $8.53.

Impact

These transactions may affect various stakeholders, including existing shareholders, potential investors, and market analysts. The activity from a ten-percent owner like Scully could signal confidence in Prothena's strategic direction and financial health, potentially influencing market perceptions and investor behavior.

What's Next

The filing does not say what happens next.